BGN and melanoma: Consistent with the concept that integrin-β1 overexpression reversed the Bgn-related survival benefit, no enhanced tumor-related mortality was seen when integrin-β1 overexpressing melanoma cells were compared to empty-vector melanoma cells in Bgn+/+ mice (Figure 5H).